📊 ELAN Key Takeaways
Is Elanco Animal Health Inc (ELAN) a Good Investment?
Elanco exhibits critical operational distress with negative free cash flow of -$38M and interest coverage of 0.5x, indicating inability to service debt from operations despite $1.4B revenue. The 169% EPS decline, 0.9% ROE, and 6.3% operating margin reveal structural profitability issues that cannot be sustained; while gross margins of 57.3% show pricing power, operational expenses and working capital management appear severely impaired.
Elanco shows modest top-line growth and still generates positive operating cash flow, but that growth is not translating into acceptable earnings quality, with operating and net losses worsening materially. The balance sheet is not distressed and liquidity is adequate, yet negative interest coverage and weak returns on equity/assets indicate the core issue remains insufficient profitability rather than lack of scale.
Why Buy Elanco Animal Health Inc Stock? ELAN Key Strengths
- Healthy gross margin of 57.3% demonstrates pricing power and cost control
- Positive revenue growth of 6.2% YoY in stable pharmaceutical sector
- Moderate leverage with 0.57x debt-to-equity ratio provides some refinancing flexibility
- Adequate short-term liquidity with 2.16x current ratio and $428M cash position
- Revenue grew 6.2% year over year, indicating the business is still expanding
- Gross margin of 55.0% suggests the product portfolio retains solid underlying economics before overhead and other charges
- Operating cash flow of $560.00M and free cash flow of $284.00M provide financial flexibility despite reported losses
ELAN Stock Risks: Elanco Animal Health Inc Investment Risks
- Negative free cash flow of -$38M on $1.4B revenue indicates severe working capital deterioration and unsustainable cash burn
- Interest coverage of 0.5x means operating income cannot service debt; existential solvency risk if debt restructuring required
- EPS collapsed 169% YoY amid only $57M net income, signaling fundamental earnings quality collapse
- Minimal returns with ROE of 0.9% and ROA of 0.4%; operating margin of 6.3% is critically low for pharmaceutical company
- Operating margin of -4.8% and net margin of -4.9% show the company is not converting revenue into profit
- Net income deteriorated sharply year over year, signaling worsening earnings quality
- Interest coverage of -1.2x and long-term debt of $3.76B create pressure if profitability does not recover
Key Metrics to Watch
- Free cash flow path to positive territory and operating cash flow improvement
- Operating margin expansion toward 12-15% pharma industry baseline
- Interest coverage ratio and debt reduction plan to achieve minimum 1.5x coverage
- EPS stabilization and whether recent deterioration represents cyclical or structural decline
- Operating margin and net income trend
- Free cash flow generation relative to debt and interest burden
Elanco Animal Health Inc (ELAN) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 2.16x current ratio provides a solid financial cushion.
ELAN Profit Margin, ROE & Profitability Analysis
ELAN vs Healthcare Sector: How Elanco Animal Health Inc Compares
How Elanco Animal Health Inc compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Elanco Animal Health Inc Stock Overvalued? ELAN Valuation Analysis 2026
Based on fundamental analysis, Elanco Animal Health Inc shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Elanco Animal Health Inc Balance Sheet: ELAN Debt, Cash & Liquidity
ELAN Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Elanco Animal Health Inc's revenue has remained relatively flat over the 5-year period, with a 1% decline. The most recent EPS of $-2.50 indicates the company is currently unprofitable.
ELAN Revenue Growth, EPS Growth & YoY Performance
ELAN Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $1.2B | $57.0M | $0.11 |
| Q3 2025 | $1.0B | $11.0M | $-0.07 |
| Q2 2025 | $1.2B | $11.0M | $0.02 |
| Q1 2025 | $1.2B | $32.0M | $0.06 |
| Q3 2024 | $1.0B | $32.0M | $0.70 |
| Q2 2024 | $1.1B | $6.0M | $0.01 |
| Q1 2024 | $1.2B | $32.0M | $0.06 |
| Q3 2023 | $1.0B | -$10.0M | $-0.05 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Elanco Animal Health Inc Dividends, Buybacks & Capital Allocation
ELAN SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Elanco Animal Health Inc (CIK: 0001739104)
📋 Recent SEC Filings
❓ Frequently Asked Questions about ELAN
What is the AI rating for ELAN?
Elanco Animal Health Inc (ELAN) has a Combined AI Rating of SELL from Claude (SELL) and ChatGPT (SELL) with 80% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are ELAN's key strengths?
Claude: Healthy gross margin of 57.3% demonstrates pricing power and cost control. Positive revenue growth of 6.2% YoY in stable pharmaceutical sector. ChatGPT: Revenue grew 6.2% year over year, indicating the business is still expanding. Gross margin of 55.0% suggests the product portfolio retains solid underlying economics before overhead and other charges.
What are the risks of investing in ELAN?
Claude: Negative free cash flow of -$38M on $1.4B revenue indicates severe working capital deterioration and unsustainable cash burn. Interest coverage of 0.5x means operating income cannot service debt; existential solvency risk if debt restructuring required. ChatGPT: Operating margin of -4.8% and net margin of -4.9% show the company is not converting revenue into profit. Net income deteriorated sharply year over year, signaling worsening earnings quality.
What is ELAN's revenue and growth?
Elanco Animal Health Inc reported revenue of $1.4B.
Does ELAN pay dividends?
Elanco Animal Health Inc does not currently pay dividends.
Where can I find ELAN SEC filings?
Official SEC filings for Elanco Animal Health Inc (CIK: 0001739104) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is ELAN's EPS?
Elanco Animal Health Inc has a diluted EPS of $0.11.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is ELAN a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Elanco Animal Health Inc has a SELL rating with 80% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is ELAN stock overvalued or undervalued?
Valuation metrics for ELAN: ROE of 0.9% (sector avg: 15%), net margin of 4.2% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy ELAN stock in 2026?
Our dual AI analysis gives Elanco Animal Health Inc a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is ELAN's free cash flow?
Elanco Animal Health Inc's operating cash flow is $13.0M, with capital expenditures of $51.0M. FCF margin is -2.8%.
How does ELAN compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 4.2% (avg: 12%), ROE 0.9% (avg: 15%), current ratio 2.16 (avg: 2).